文献速递类风湿关节炎

巴瑞替尼II期和III期汇总研究中的血脂谱及他汀治疗效果

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.
PubMed 文献 · Ann Rheum Dis · 2018-02-20

该分析基于巴瑞替尼4 mg(n=997)和2 mg(n=479)治疗中重度活动性类风湿关节炎的II期和III期研究,发现巴瑞替尼与总胆固醇、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)和甘油三酯水平升高相关,但LDL-C:HDL-C比值无显著变化,血脂水平在治疗12周后趋于稳定。基线使用他汀者与未使用者的血脂变化无显著差异;研究期间启动他汀治疗的患者中,LDL-C、甘油三酯(仅4 mg组)和载脂蛋白B降至巴瑞替尼治疗前水平,而HDL-C和载脂蛋白A-I仍保持升高。

要点

  • 巴瑞替尼治疗与总胆固醇、LDL-C、HDL-C和甘油三酯升高相关,但LDL-C:HDL-C比值无显著变化。
  • 血脂水平在治疗12周后趋于稳定,基线他汀使用与否对血脂变化无显著影响。
  • 研究期间启动他汀治疗可使LDL-C等指标降至治疗前水平,但HDL-C仍保持升高。

核心结论

  • 巴瑞替尼与LDL-C、HDL-C和甘油三酯水平升高相关,但未改变LDL-C:HDL-C比值。
  • 作者认为需要评估长期治疗期间的心血管事件发生率,以进一步描述这些发现及其可能的临床意义。

研究设计与样本

  • 分析来自巴瑞替尼4 mg(n=997)和2 mg(n=479)每日一次口服治疗中重度活动性类风湿关节炎的II期和III期研究的血脂数据。
  • 在一项III期研究中采用核磁共振评估脂蛋白颗粒大小、数量及GlycA。
  • 在基线使用他汀的患者和研究期间启动他汀的患者中评估他汀治疗对血脂水平的影响。

主要发现

  • 巴瑞替尼治疗与总胆固醇、LDL-C、HDL-C和甘油三酯水平升高相关,但LDL-C:HDL-C比值无显著变化。
  • 血脂水平在治疗12周后趋于稳定。
  • 巴瑞替尼治疗增加大LDL颗粒数量,减少小而密LDL颗粒数量及GlycA。
  • 基线他汀使用者与非使用者的血脂自基线变化无显著差异。
  • 研究期间启动他汀治疗的患者中,LDL-C、甘油三酯(仅巴瑞替尼4 mg组)和载脂蛋白B降至巴瑞替尼治疗前水平;HDL-C和载脂蛋白A-I水平仍保持升高。

局限性

  • 作者认为需要评估长期治疗期间的心血管事件发生率,以进一步描述这些发现及其可能的临床意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Lipid profiles are altered by active disease in patients with rheumatoid arthritis (RA) and may be further modified by treatment with Janus kinase inhibitors and other disease-modifying antirheumatic drugs. METHODS: Lipid data were analysed from phase II and III studies of 4 mg (n=997) and 2 mg (n=479) oral baricitinib administered once daily in patients with moderate-to-severe active RA. Lipoprotein particle size and number and GlycA were evaluated with nuclear magnetic resonance in one phase III study. The effect of statin therapy on lipid levels was evaluated in patients on statins at baseline and in patients who initiated statins during the study. RESULTS: Treatment with baricitinib was associated with increased levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides, but no significant change in LDL-C:HDL-C ratio. Lipid levels plateaued after 12 weeks of treatment. Baricitinib treatment increased large LDL and decreased small, dense LDL particle numbers and GlycA. Lipid changes from baseline were not significantly different between baseline statin users and non-users. In patients who initiated statin therapy during the study, LDL-C, triglycerides (baricitinib 4 mg only) and apolipoprotein B decreased to pre-baricitinib levels; HDL-C and apolipoprotein A-I levels remained elevated. CONCLUSIONS: Baricitinib was associated with increased LDL-C, HDL-C and triglyceride levels, but did not alter the LDL-C:HDL-C ratio. Evaluation of cardiovascular event rates during long-term treatment is warranted to further characterise these findings and their possible clinical implications. TRIAL REGISTRATION NUMBER: NCT00902486, NCT01469013, NCT01185353, NCT01721044, NCT01721057, NCT01711359, NCT01710358, NCT01885078.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Taylor PC, Kremer JM, Emery P, et al. Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. Ann Rheum Dis. 2018. PMID: 29463520. doi:10.1136/annrheumdis-2017-212461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。